Abstract: From cross-sectional genotypic analyses, the
K65R mutation and TAMs appear to represent separate patterns of
NRTI resistance.
Abstract: From in vitro phenotypic analysis, the
K65R mutation shows no cross-resistance to zidovudine, but low-level resistance to tenofovir and the other
NRTIs.